Literature DB >> 22427407

Impaired quality of life after chikungunya virus infection: a 2-year follow-up study.

Elisabeth Couturier1, Francis Guillemin, Marie Mura, Lucie Léon, Jean-Marc Virion, Marie-José Letort, Henriette De Valk, Fabrice Simon, Véronique Vaillant.   

Abstract

OBJECTIVES: To measure the frequency of and risk factors for rheumatic manifestations after chikungunya virus (CHIKV) infection and to assess their impact on quality of life (QoL).
METHODS: In a cohort study among 509 cases diagnosed in France, demographic and clinical characteristics were collected at baseline, and QoL status by 36-item short-form health survey (SF-36), a short form of the Arthritis Impact Measurement Scales 2 (AIMS2-SF) and General Health Questionnaire (GHQ-12) at follow-up. SF-36 scores were compared with population norms. Factors associated with QoL were identified in multivariate linear regression models.
RESULTS: A total of 391 (77%) patients participated (53.5% female, mean age 50.2 years). Median time from onset at follow-up was 23.4 months. Among 176 recovered patients, a shorter duration of symptoms was observed in younger age groups and male patients. The probability of full recovery at 1 year was 0.39. Those not recovered were older, had more comorbidities and a longer acute stage with joint swelling. Scores of physical and mental components of the SF-36 and GHQ-12 were low. The AIMS2-SF was affected mainly in symptoms, psychological and social dimensions. Recovered patients did not differ significantly from age- and gender-matched population SF-36 norms. Older age (P = 0.01-0.002) was associated with lower SF-36 scores. Other factors associated with lower SF-36, lower GHQ12 scores and higher AIMS2-SF dimensions were lack of recovery (P = 0.017 to <0.0001), presence of comorbidity (P = 0.005 to <0.0001) and a longer duration of acute stage (P = 0.047 to <0.0001).
CONCLUSION: Medical follow-up with special attention to comorbidity providing information on possible chronic symptoms and giving support for potential depression and anxiety are recommended.

Entities:  

Mesh:

Year:  2012        PMID: 22427407     DOI: 10.1093/rheumatology/kes015

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  45 in total

1.  Chikungunya Virus Disease among Travelers-United States, 2014-2016.

Authors:  Nicole P Lindsey; J Erin Staples; Marc Fischer
Journal:  Am J Trop Med Hyg       Date:  2018-01-01       Impact factor: 2.345

Review 2.  Animal Models of Chikungunya Virus Infection and Disease.

Authors:  Nicole N Haese; Rebecca M Broeckel; David W Hawman; Mark T Heise; Thomas E Morrison; Daniel N Streblow
Journal:  J Infect Dis       Date:  2016-12-15       Impact factor: 5.226

3.  Impaired quality of life after chikungunya virus infection: a 12-month follow-up study of its chronic inflammatory rheumatism in La Virginia, Risaralda, Colombia.

Authors:  Alfonso J Rodriguez-Morales; Victor Manuel Restrepo-Posada; Nathalia Acevedo-Escalante; Esteban David Rodríguez-Muñoz; Manuela Valencia-Marín; Juan D Castrillón-Spitia; José J Londoño; Hector D Bedoya-Rendón; Javier de Jesús Cárdenas-Pérez; Jaime A Cardona-Ospina; Guillermo J Lagos-Grisales
Journal:  Rheumatol Int       Date:  2017-08-21       Impact factor: 2.631

Review 4.  Chikungunya virus: epidemiology, replication, disease mechanisms, and prospective intervention strategies.

Authors:  Laurie A Silva; Terence S Dermody
Journal:  J Clin Invest       Date:  2017-03-01       Impact factor: 14.808

5.  Chikungunya Arthritis Mechanisms in the Americas: A Cross-Sectional Analysis of Chikungunya Arthritis Patients Twenty-Two Months After Infection Demonstrating No Detectable Viral Persistence in Synovial Fluid.

Authors:  Aileen Y Chang; Karen A O Martins; Liliana Encinales; St Patrick Reid; Marlon Acuña; Carlos Encinales; Christian B Matranga; Nelly Pacheco; Carlos Cure; Bhavarth Shukla; Teofilo Ruiz Arteta; Richard Amdur; Lisa H Cazares; Melissa Gregory; Michael D Ward; Alexandra Porras; Alejandro Rico Mendoza; Lian Dong; Tara Kenny; Ernie Brueggemann; Lydia G Downey; Priyanka Kamalapathy; Paola Lichtenberger; Orlando Falls; Gary L Simon; Jeffrey M Bethony; Gary S Firestein
Journal:  Arthritis Rheumatol       Date:  2018-03-07       Impact factor: 10.995

6.  Pathogenic Chikungunya Virus Evades B Cell Responses to Establish Persistence.

Authors:  David W Hawman; Julie M Fox; Alison W Ashbrook; Nicholas A May; Kristin M S Schroeder; Raul M Torres; James E Crowe; Terence S Dermody; Michael S Diamond; Thomas E Morrison
Journal:  Cell Rep       Date:  2016-07-21       Impact factor: 9.423

7.  Prime-boost immunization strategies against Chikungunya virus.

Authors:  David Hallengärd; Fok-Moon Lum; Beate M Kümmerer; Aleksei Lulla; Valeria Lulla; Juan García-Arriaza; John K Fazakerley; Pierre Roques; Roger Le Grand; Andres Merits; Lisa F P Ng; Mariano Esteban; Peter Liljeström
Journal:  J Virol       Date:  2014-09-10       Impact factor: 5.103

8.  Chronic joint disease caused by persistent Chikungunya virus infection is controlled by the adaptive immune response.

Authors:  David W Hawman; Kristina A Stoermer; Stephanie A Montgomery; Pankaj Pal; Lauren Oko; Michael S Diamond; Thomas E Morrison
Journal:  J Virol       Date:  2013-10-16       Impact factor: 5.103

9.  Protection against Chikungunya virus induced arthralgia following prophylactic treatment with adenovirus vectored interferon (mDEF201).

Authors:  Ashley Dagley; Jane Ennis; Jeffrey D Turner; Kerry A Rood; Arnaud J Van Wettere; Brian B Gowen; Justin G Julander
Journal:  Antiviral Res       Date:  2014-05-14       Impact factor: 5.970

10.  A single-amino-acid polymorphism in Chikungunya virus E2 glycoprotein influences glycosaminoglycan utilization.

Authors:  Laurie A Silva; Solomiia Khomandiak; Alison W Ashbrook; Romy Weller; Mark T Heise; Thomas E Morrison; Terence S Dermody
Journal:  J Virol       Date:  2013-12-26       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.